Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves
- 31 August 2005
- journal article
- clinical trial
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 95 (2), 181-189
- https://doi.org/10.1016/s1081-1206(10)61209-4
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthmaAnnals of Allergy, Asthma & Immunology, 2002
- Psychopathology in Patients with Severe Asthma Is Associated with Increased Health Care UtilizationAmerican Journal of Respiratory and Critical Care Medicine, 2001
- The health economics of asthma and rhinitis. I. Assessing the economic impactJournal of Allergy and Clinical Immunology, 2001
- Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 μ g twice daily and budesonide 800 μ g twice daily in the treatment of adults and adolescents with asthmaRespiratory Medicine, 2000
- Risk factors and costs associated with an asthma attackThorax, 2000
- Concurrent Use of Salmeterol with Inhaled Corticosteroids is More Effective than Inhaled Corticosteroid Dose IncreasesAllergy and Asthma Proceedings, 1999
- The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthmaAnnals of Allergy, Asthma & Immunology, 1999
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaNew England Journal of Medicine, 1997
- Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.American Journal of Respiratory and Critical Care Medicine, 1996
- Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroidThe Lancet, 1994